Background: Non-steroidal anti-inflammatory drugs (NSAIDs) hypersensitivity is one of the leading cause of adverse reactions and a matter of concern in susceptible patients, with NSAIDs induced urticaria/angioedema (NIUA) being the commonest phenotype. Positive associations between the human leukocyte antigen (HLA) and NSAIDs hypersensitivity have been observed in different populations.
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Objectives: The aims of this study were to determine the frequency of HLA genes in NIUA patients and NSAID-tolerant controls and, demonstrate the HLA associations of NIUA in a Malay population.
Method: 35 Malay patients with at least two chemically different NSAIDs hypersensitivity of the NIUA phenotype and 35 NSAIDs-tolerant controls following the 2013 European Network for Drug Allergy (ENDA) guideline for NSAIDs hypersensitivity were recruited. These subjects were genotyped for HLA-A, -B, -DRB1 and -DQB1 using polymerase chain reaction sequence-specific oligonucleotide probe hybridisation (PCR-SSO) method. A haplotype analysis was performed comparing the NIUA cases with 951 normal healthy controls.
Results: The frequency of HLA-A*11:01 alleles was 27.1% in the NIUA group, compared with 8.6% in the NSAIDs tolerant group (odds ratio [OR] = 3.35, 95% confidence interval [CI] = 1.31-8.60, P < 0.05). The haplotype analysis revealed that HLA-A*11:01-B*15:02-DRB1*12:02-DQB1*03:01 and HLA-A*11:01-B*15:13-DRB1*12:02-DQB1*03:01 were significantly higher in NIUA (11.4% and 5.71% respectively) than in normal healthy controls (1.1%, OR = 11.76, 95% CI = 3.50-39.52, P = 0.001 and 0.21%, OR = 28.76, 95% CI = 3.93-210.48, P = 0.007 respectively).
Conclusions:
These findings showed that HLA-A*11:01 was positively associated with NIUA in a Malay population. The haplotype findings also suggest that the HLA-A*11:01-B*15:02-DRB1*12:02-DQB1*03:01 and HLA-A*11:01-B*15:13-DRB1*12:02-DQB1*03:01 may be used as genetic markers to determine the NIUA phenotype in this population. Immunology Department, Sir Charles Gairdner Hospital, Perth, Australia
P12 THE RATE OF ATOPIC DISEASES IN CHILDREN WITH REPORTED ANTIBIOTIC ALLERGIES
Background: There has been a significant rise of allergies in children worldwide. This includes adverse reaction to antibiotics, especially betalactam. To date, there is very limited knowledge if underlying atopy is increased in children with adverse drug reactions.
Methods: Clinical history from children with reported antibiotic allergy (AAL) who presented to Princess Margaret Hospital was prospectively assessed for the rate of underlying atopic diseases from the Children Antibiotic De-labelling study (ChAD). Details such as the culprit antibiotic, initial indication for treatment, age and type of reaction were collected together with the child and family history (parents or siblings) of atopy.
Results: Datasets from 210 children (107 males) had a reported betalactam AAL. Of those 34 (16.2%) had a second allergy to another antibiotic and two cases (1.0%) had a third non beta-lactam AAL. Amongst the 246 reported AAL, the majority was related to amoxicillin (n = 138, 56.1%) and benzylpenicillin (n = 54, 22.0%).The predominant indications for prescription were ENT infections (n = 110, 44.7%). In terms of reaction, patients presented with non-urticarial rashes (n = 183, 52.4%), urticarial rashes (n = 72, 20.6%), angioedema (n = 30, 8.6%) and gastro-intestinal symptoms (n = 40, 11.5%). Anaphylaxis was reported in 19 cases (5.4%). Of those with AAL, 45.2% had a history of atopic diseases, 14.9% had underlying eczema, 8.2% food allergies, 21.6% asthma and 13.9% hay fever; 69.1% had at least one family member with a history of AAL and/or atopic disease.
Conclusion: This is the first study looking at underlying atopic diseases in children with AAL. If confirmed, antibiotic allergy associated with other atopic diseases in children remains to be seen. Background: Anaphylaxis is a severe allergic reaction characterised by potentially life-threatening cardiovascular and/or respiratory collapse. The Royal Melbourne Hospital (RMH), one of the largest hospitals in Victoria, has an average of 118 patients presenting to the Emergency Department (ED) with anaphylaxis per annum. This study examines the characteristics of this cohort and aims to identify how referral to the Allergy and Immunology Department may affect management.
Method: Sequential cases admitted to the RMH ED with anaphylaxis over a 6-month period were identified via discharge coding. These patients' medical records were retrospectively audited regarding the reaction, in-patient management, provision of an adrenaline auto-injector and anaphylaxis action plan and Immunology department referral.
Results: 51 cases were reviewed. Food was the most common cause of anaphylaxis. No culprit agent was identified in 19% of cases (see Fig. 1 ). Adrenaline was administered to 41 patients, most commonly in the emergency department (22 cases). 34 patients were prescribed an adrenaline auto-injector on discharge. Four cases were identified where an adrenaline auto-injector was clearly indicated, but was not prescribed. Approximately one-quarter of patients were referred to the Immunology unit as an inpatient. This group accounted for over half of the cases documented to have received an anaphylaxis action plan and all but one of the cases documented to have received advice on avoidance of potential triggers. A further 11 patients were referred for outpatient review. 
